R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML)
Status:
Completed
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine how efficient the combination of rituximab,
cyclophosphamide, vincristine, and prednisolone (R-CVP) is in the treatment of stage I or II
non-conjunctival ocular adnexal MALT lymphoma (OAML).